BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Nirmal Bang Report
We attended the analyst meet conducted by GlaoxSmithKline Pharmaceuticals Ltd. to get an insight into the company’s business outlook.
The company’s 78% business comes from prescription and 22% from vaccines. The Rx business is skewed towards the acute segment (~95% of portfolio), which due to seasonality benefit, is expected to deliver strong growth in Q2 FY23.
GSK Pharma has also guided for ~8-9% price hike in FY23. The future levers for Ebitda margin expansion would be centered around:
growth in promoted brands,
new launches,
cost-saving initiatives and
improved medical representative productivity.
The main pain point for the company still remains the vaccine business; the broad vaccine industry growth has remained sluggish due to vaccine hesitancy and postponement of inoculation by the masses. But, the company has maintained its market share and expects demand to recover by the end of FY23.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR